Han Kyung-Do, Park Sang-Hyun, Son Sumin, Kim Seung-Ho, Kim Ikhee, Kim Jong-Yeup, In Seung-Min, Kim Yeon-Soo, Lee Ki-Il
Department of Statistics and Actuarial Science, Soongsil University, Seoul 03080, Korea.
Department of Medical Statistics, College of Medicine, Catholic University of Korea, Seoul 03080, Korea.
J Clin Med. 2022 Sep 9;11(18):5316. doi: 10.3390/jcm11185316.
We analyzed the relationship between chronic rhinosinusitis (CRS) and the incidence of head and neck cancers (HNCs) in a Korean adult population. This retrospective cohort study included data from the Korean National Health Insurance Service database. Adjustments were made to minimize risk variables for sex, age, diabetes, hypertension, dyslipidemia, and rhinitis between the two groups. The primary endpoint was newly diagnosed HNC between January 2009 and December 2018. Among 1,337,120 subjects in the Korean National Health Insurance Service database, data from 324,774 diagnosed with CRS (CRS group) and 649,548 control subjects (control group) were selected. Patients with CRS exhibited a statistically significant greater risk for nasal cavity/paranasal sinus cancer, hypopharynx/larynx cancer, and thyroid cancer compared with the control group. In the CRS group, the adjusted hazard ratios for nasal cavity/paranasal sinus cancer were 1.809 (95% confidence interval (CI) 1.085-3.016), 1.343 (95% CI 1.031-1.748) for hypopharynx and larynx cancer, and 1.116 (95% CI 1.063-1.173) for thyroid cancer. CRS was associated with a higher incidence of HNCs. Therefore, physicians should carefully consider the possibility of HNC progression and implement therapeutic strategies to minimize the impact of these diseases.
我们分析了韩国成年人群中慢性鼻-鼻窦炎(CRS)与头颈癌(HNC)发病率之间的关系。这项回顾性队列研究纳入了韩国国民健康保险服务数据库中的数据。对两组之间的性别、年龄、糖尿病、高血压、血脂异常和鼻炎等风险变量进行了调整,以使其最小化。主要终点是2009年1月至2018年12月期间新诊断的头颈癌。在韩国国民健康保险服务数据库的1337120名受试者中,选取了324774名被诊断为CRS的受试者(CRS组)和649548名对照受试者(对照组)的数据。与对照组相比,CRS患者患鼻腔/鼻窦癌、下咽/喉癌和甲状腺癌的风险在统计学上显著更高。在CRS组中,鼻腔/鼻窦癌的调整后风险比为1.809(95%置信区间(CI)1.085 - 3.016),下咽和喉癌为1.343(95%CI 1.031 - 1.748),甲状腺癌为1.116(95%CI 1.063 - 1.173)。CRS与头颈癌的较高发病率相关。因此,医生应仔细考虑头颈癌进展的可能性,并实施治疗策略以尽量减少这些疾病的影响。